search
Back to results

Effect of Zopiclone on Compliance With Continuous Positive Airway Pressure in Obstructive Sleep Apnea

Primary Purpose

Obstructive Sleep Apnea

Status
Completed
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
Placebo
Zopiclone
Sponsored by
OSR Medical Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obstructive Sleep Apnea

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • MD diagnosis of obstructive sleep apnea
  • No previous use of CPAP
  • No concurrent use of hypnotic medication

Exclusion Criteria:

  • Fatal comorbidities (i.e., life expectancy less than 6 months)
  • Contraindications for CPAP use
  • Pregnancy
  • Liver Failure

Sites / Locations

  • Cite de la Sante
  • Institut de medecine specialisee de Laval
  • Institut de Medecine du sommeil
  • Mount Sinai Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Placebo

zopiclone

Arm Description

Usual sleep apnea and CPAP care Sleep apnea OSR Medical Treatment Plan©

Sleep apnea OSR Medical Treatment plan ©

Outcomes

Primary Outcome Measures

CPAP adherence

Secondary Outcome Measures

ESS and SAQLI scores, changes from baseline, % time of average CPAP usage over the last month/ self-estimated total sleep time (h). Residual AHI monitored, analysed for similar findings at trial closure and analysis, but is not an efficacy parameter

Full Information

First Posted
June 7, 2011
Last Updated
July 16, 2015
Sponsor
OSR Medical Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01369576
Brief Title
Effect of Zopiclone on Compliance With Continuous Positive Airway Pressure in Obstructive Sleep Apnea
Official Title
A Double-blind, Randomized, Parallel Group Study to Determine the Effect of Initial Prescription of Zopiclone on the Level of Compliance With CPAP in Adult Patients Treated for OSA at 26 Weeks
Study Type
Interventional

2. Study Status

Record Verification Date
July 2015
Overall Recruitment Status
Completed
Study Start Date
May 2011 (undefined)
Primary Completion Date
May 2014 (Actual)
Study Completion Date
November 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
OSR Medical Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The clinical population targeted will be newly diagnosed patients with polysomnographically diagnosed OSA who are not currently taking hypnotics for concomitantly diagnosed insomnia. Outpatients who are also judged to be capable to follow the study procedures (consent, timelines, visits, questionnaires) and who do not have any concurrent disease that in the view of the investigator will interfere with participation in the trial to completion will be included. Approximately 160 subjects were recruited (80 per treatment arm) in the recent trial of eszopiclone. This size is expected to be able to discern an important difference of 80 minutes per night. In the current clinical population newly prescribed CPAP at Mount Sinai Hospital, the average compliance after 4 weeks of initiation of nCPAP was 4:01 (SD 2:59) hours per night. To be able to discern a difference of at least 1 hour (60 minutes) in usage per night, including entirely non-adherent patients who do not use treatment at all as 'zero hour' users, would require randomization of 264 patients (132 per group). Our hypothesis for this study is that initial titration of CPAP treatment of OSA may be improved by initial prescription of a common hypnotic, zopiclone. To answer this question we intend to recruit 264 consecutive consenting subjects with OSA confirmed by a physician (ABSM or by a respirologist with extensive sleep medicine experience) with supportive polysomnography results who are willing to initiate long-term CPAP treatment.
Detailed Description
Background: Obstructive sleep apnea (OSA) is a common sleep breathing disorder that is associated with serious complications. Continuous positive airway pressure (CPAP) is the treatment of choice for most patients but its use in the real world is limited by low patient adherence which may result in sub-optimal outcomes for some patients. A single hypnotic with low risk of adverse effects is a cost-effective intervention to augment the currently low adherence to CPAP, especially if only prescribed for a limited time. The hypnotic is generic zopiclone 3.75-7.5 mg at bedtime for up to 14 doses. The clinical population targeted will be newly expert physician-diagnosed patients polysomnographically supported OSA who are not currently taking hypnotics for concomitantly diagnosed insomnia. Outpatients who are also judged to be capable to follow the study procedures (consent, timelines, visits, questionnaires) and who do not have any concurrent disease that in the view of the investigator will interfere with participation in the trial to completion will be included.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obstructive Sleep Apnea

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
264 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Usual sleep apnea and CPAP care Sleep apnea OSR Medical Treatment Plan©
Arm Title
zopiclone
Arm Type
Experimental
Arm Description
Sleep apnea OSR Medical Treatment plan ©
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
3.75-7.5mg 14 doses 4 weeks
Intervention Type
Drug
Intervention Name(s)
Zopiclone
Intervention Description
3.75-7.5mg 14 doses 4 weeks
Primary Outcome Measure Information:
Title
CPAP adherence
Time Frame
6 months
Secondary Outcome Measure Information:
Title
ESS and SAQLI scores, changes from baseline, % time of average CPAP usage over the last month/ self-estimated total sleep time (h). Residual AHI monitored, analysed for similar findings at trial closure and analysis, but is not an efficacy parameter
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: MD diagnosis of obstructive sleep apnea No previous use of CPAP No concurrent use of hypnotic medication Exclusion Criteria: Fatal comorbidities (i.e., life expectancy less than 6 months) Contraindications for CPAP use Pregnancy Liver Failure
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paul Verschelden, MD DABSM
Organizational Affiliation
Cite de la Sante, University of Montreal, OSR Medical, Institut de medecine specialisee de Laval (IMSL)
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Marcel Baltzan, MDCM DABSM
Organizational Affiliation
McGill University, OSR Medical, Institut de medecine du sommeil (IMS)
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kateri Champagne, MD DABSM
Organizational Affiliation
McGill University Health Centre (MUHC), OSR Medical, Institut de medecine du sommeil (IMS)
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Germaine Tanzimat, RN
Organizational Affiliation
OSR Medical Inc.
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Barbara Capozzolo, MSc
Organizational Affiliation
OSR Medical Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cite de la Sante
City
Laval
State/Province
Quebec
ZIP/Postal Code
H7M 3L9
Country
Canada
Facility Name
Institut de medecine specialisee de Laval
City
Laval
State/Province
Quebec
ZIP/Postal Code
H7S 2M5
Country
Canada
Facility Name
Institut de Medecine du sommeil
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H4N 1C5
Country
Canada
Facility Name
Mount Sinai Hospital
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H4W 1S7
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
18949106
Citation
Wolkove N, Baltzan M, Kamel H, Dabrusin R, Palayew M. Long-term compliance with continuous positive airway pressure in patients with obstructive sleep apnea. Can Respir J. 2008 Oct;15(7):365-9. doi: 10.1155/2008/534372.
Results Reference
background
PubMed Identifier
18250209
Citation
Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc Am Thorac Soc. 2008 Feb 15;5(2):173-8. doi: 10.1513/pats.200708-119MG.
Results Reference
background
PubMed Identifier
19370691
Citation
Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines for adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007736. doi: 10.1002/14651858.CD007736.
Results Reference
background
PubMed Identifier
19920270
Citation
Lettieri CJ, Shah AA, Holley AB, Kelly WF, Chang AS, Roop SA; CPAP Promotion and Prognosis-The Army Sleep Apnea Program Trial. Effects of a short course of eszopiclone on continuous positive airway pressure adherence: a randomized trial. Ann Intern Med. 2009 Nov 17;151(10):696-702. doi: 10.7326/0003-4819-151-10-200911170-00006.
Results Reference
background
PubMed Identifier
19567493
Citation
Lettieri CJ, Collen JF, Eliasson AH, Quast TM. Sedative use during continuous positive airway pressure titration improves subsequent compliance: a randomized, double-blind, placebo-controlled trial. Chest. 2009 Nov;136(5):1263-1268. doi: 10.1378/chest.09-0811. Epub 2009 Jun 30.
Results Reference
background

Learn more about this trial

Effect of Zopiclone on Compliance With Continuous Positive Airway Pressure in Obstructive Sleep Apnea

We'll reach out to this number within 24 hrs